Vivozon Pharmaceutical Co (082800) Fair Value & Analysis
Healthcare · KR · Market cap 145B KRW
Fair value as of: Jul 22, 2026
From 1 valuation models · updated 19 days ago
Share price +9.6% over the past month.
Below-average quality, and screening another 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (975.88 KRW). The favourable scenario is already priced in.
- Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (487.94 KRW to 975.88 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,956 KRW – 10,636 KRW · fair‑value band 487.94 KRW – 975.88 KRW · the 2,865 KRW price screens above the 653.84 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Vivozon Pharmaceutical Co (082800) currently trades at 2,865 KRW, while our model-based Fair Value estimate is 653.84 KRW, implying the stock looks roughly 77.2% overvalued today. The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 59.9B KRW. Revenue grew 8.5% year over year. Net debt stands at 37.8B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 487.94 KRW (bear case) to 975.88 KRW (bull case); at 2,865 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high and 33% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -77%, 082800 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 082800 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 29 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications.
Full company description
Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications. It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as well as lights for parking lots. In addition, the company operates Echo House, a lighting show room that sells LED florescent lamps, LED flat lamps, LED PAR lamps, LED bulb lamps, and home LED lightings. The company was formerly known as Vivozon Healthcare, Inc. and changed its name to Vivozon Pharmaceutical Co., Ltd. in November 2022. Vivozon Pharmaceutical Co., Ltd. was founded in 2002 and is based in Yongin, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vivozon Pharmaceutical Co reported revenue of 59.3B KRW in FY2025 versus 57.7B KRW in FY2021, a compound +0.7%/yr. Reported net income was −32.4B KRW in FY2025.
082800 screens 77% overvalued. Compare with GlaxoSmithKline Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,653 | ₹1,471 | -45% |
| Caregen Co 214370 | 62,700 KRW | 7,277 KRW | -88% |
| ST Pharm Co 237690 | 123,600 KRW | 50,110 KRW | -59% |
| Oscotec Inc 039200 | 31,050 KRW | 25,062 KRW | -19% |
| DongKook Pharmaceutical Co 086450 | 18,350 KRW | 32,142 KRW | +75% |
| Kolon Life Science Inc 102940 | 30,100 KRW | 37,195 KRW | +24% |
| Huons Global Co 084110 | 23,800 KRW | 58,482 KRW | +146% |
| BINEX Co 053030 | 6,350 KRW | 1,844 KRW | -71% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 16,810 KRW | 4,741 KRW | -72% |
| EURO EURO | 1.09 PHP | 0.8700 PHP | -20% |
Compare Vivozon Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vivozon Pharmaceutical Co (082800) overvalued or undervalued?
What is the fair value of 082800?
What is the quality score of 082800?
What is the revenue of Vivozon Pharmaceutical Co (082800)?
What is the net profit margin of 082800?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vivozon Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.